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Abstract: A novel, quick, reliable and simple capillary zone electrophoresis CZE method was developed and validated for the simulta-
neous determination of sitagliptin (SG) and metformin (MF) in pharmaceutical preparations. Separation was carried out in fused silica 
capillary (50.0 cm total length and 43.0 cm effective length, 49 µm i.d.) by applying a potential of 15 KV (positive polarity) and a run-
ning buffer containing 60 mM phosphate buffer at pH 4.0 with UV detection at 203 nm. The samples were injected hydrodynamically 
for 3 s at 0.5 psi and the temperature of the capillary cartridge was kept at 25 °C. Phenformin was used as internal standard (IS).
The method was suitably validated with respect to specificity, linearity, limit of detection and quantitation, accuracy, precision, and 
robustness. The method showed good linearity in the ranges of 10–100 µg/mL and 50–500 µg/mL with limits of detection of 0.49, 
2.11 µg/mL and limits of quantification of 1.48, 6.39 µg/mL for SG and MF, respectively. The proposed method was successfully 
applied for the analysis of the studied drugs in their synthetic mixtures and co-formulated tablets without interfering peaks due to the 
excipients present in the pharmaceutical tablets. The method was further extended to the in-vitro determination of the two drugs in 
spiked human plasma. The estimated amounts of SG/MF were almost identical with the certified values, and their percentage relative 
standard deviation values (% R.S.D.) were found to be #1.50% (n = 3). The results were compared to a reference method reported in 
the literature and no significant difference was found statistically.
Keywords: sitagliptin, metformin, simultaneous determination, capillary zone electrophoresis, validation, pharmaceutical preparations, 
human plasma
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Introduction
As the number of individuals affected by diabetes 
is continuing to increase worldwide, the need for 
effective management assumes ever greater urgency. 
Newer classes of medications, particularly those 
which work via the incretin pathway, achieve glucose 
lowering and minimizing risks associated with more 
traditional therapies. Ideally, combination therapies 
should be well tolerated, convenient to take, have few 
contraindications, have a low risk of  hypoglycemia 
and weight gain, and be reasonably effective over 
both the short and long term such as the combination 
of metformin (MF) and the dipeptidyl peptidase-4 
(DPP-4) inhibitor sitagliptin (SG).1
Sitagliptin (SG) 2R)-4-oxo-4-[3-(trifluoromethyl)-
5,6-dihydro[1 ,2 ,4] t r iazolo[4 ,3-a]pyrazin-7 
(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine; 
7-[(3R)-3-Amino-1-oxo-4-(2,4,5-trifluoro phenyl)
butyl]-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-
triazolo[4,3-a]pyrazine phosphate (1:1) monohydrate 
(Fig. 1A) is a novel selective inhibitor of DPP-4.2 SG 
has recently been approved in USA and Europe for 
treatment of type 2 diabetes mellitus (T2DM). Like 
other DPP-4 inhibitors, SG is responsible for the rapid 
degradation of the incretin hormones, glucagon-like 
peptide-1 (GLP-1) and glucose dependent insulino-
tropic peptide (GIP), which is released from the gut in 
response to food intake and reduces hemoglobin A1c 
(HbA1c), fasting and postprandial glucose by glucose-
dependent stimulation of insulin secretion and inhibi-
tion of glucagon secretion.3
Metformin (MF) N,N-dimethyldiguanide hydro-
chloride (Fig. 1B), is an inexpensive biguanide oral 
antihyperglycemic agent,2 it exerts its glucose- lowering 
A
B
C H
N
H
N
NH NH
NH2
NH2
NH2
•  HCl
N
N
N • H3PO4   • H2O
N
F
O
F
F
F
F
F
H
NN
NH NH
•  HCl
Figure 1. The structural formulae for the studied drugs. (A) sitagliptin phosphate monohydrate (Sg), (B) metformin hydrochloride (MF) and (c) phenformin 
hydrochloride (IS).
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effects primarily through increased hepatic insulin 
sensitivity and the resultant suppression of hepatic 
glucose output. MF may also modestly enhance glu-
cose uptake in peripheral tissues and increase glucose 
metabolism in the splanchnic bed.4
SG and MF exert a complementary glucose-
 lowering effect and represent a well-tolerated option 
for patients requiring therapy for T2DM.1
Because SG is a new product and recently intro-
duced in the market, it is not yet official in any of the 
pharmacopoeias but MF is official in British Pharma-
copeia (BP)5 and United State Pharmacopeia (USP).6
Literature survey reveals several methods for the 
determination of SG in pharmaceutical preparation 
or biological fluids including spectrophotometry7,8 
liquid chromatography-tendem mass spectroscopy 
(LC-MS/MS)9–11 and only one capillary electropho-
resis method.12
Several methods have also been described for the 
determination of MF either alone or in combination with 
various drugs, such as spectrophotometry,13,14 LC,15–17 
LC/MS–MS18–20 and capillary electrophoresis.21–23
Regarding SG and MF simultaneous analysis, 
two spectroscopic methods have been reported for 
the simultaneous determination of both drugs in 
pharmaceutical preparations24,25 and only three chro-
matographic methods have been reported for their 
determination in pharmaceutical preparations.26–28
To the best of our knowledge, no capillary elec-
trophoresis method was reported yet for the simulta-
neous determination of the studied drugs neither in 
pharmaceutical preparations nor in biological fluids.
The use of capillary electrophoresis (CE) methods 
for pharmaceutical analysis has become increasingly 
popular in recent years. The wide range of pharma-
ceutical applications for which its use has proved 
successful, includes assay of drugs, determination of 
drug-related impurities, physicochemical measure-
ments of drug molecules, chiral separation, and the 
analysis of vitamins and pharmaceutical  excipients. 
The advantages of using CE for pharmaceutical 
analysis include its speed and low cost of analysis, 
reductions in solvent consumption and disposal, and 
the possibility of rapid method development. CE also 
offers the possibility that a single set of separation 
conditions can be applied for a wide range of analyses, 
giving efficiency savings.29,30 Recently, CE techniques 
have been applied to the  simultaneous determination 
of co-formulated drugs in dosage form.31,32
This study aimed to develop and validate a rapid, 
accurate, inexpensive and selective method by cap-
illary electrophoresis applied to the routine quality 
control analysis of SG and MF simultaneously in their 
co-formulated tablets and in human plasma. SG and 
MF are co-formulated in a medicinally recommended 
ratio of 1:10 and 1:20 (calculated as sitagliptin base 
and metformin HCL). Analysis of such mixture with 
strong spectral overlapping is challenging. The pro-
posed CZE method allowed the separation and quan-
titation of the two drugs with satisfied accuracy and 
precision. Because this method consumes no organic 
solvent, it can be considered a green method.
experimental
Apparatus
The assay was developed and validated using a 
Beckman P/ACE 5510 system (Fullerton, CA, 
USA) equipped with an autosampler, a photodiode 
array (PDA) detector, a temperature controlling 
system(4 °C–40 °C) and power supply able to deliver 
up to 30 KV. Beckman P/ACETM station software 
(version 1.2) was used for the instrument control, 
data acquisition and analysis.
Electrophoretic analyses were performed in a 
fused silica capillary (Polymicro Technologies, Phoe-
nix, AZ, USA) of 50.0-cm-long (43.0-cm effective 
length) and 49.0 µm i.d. in normal mode, applying 
a voltage of 15 KV. The wavelength for analysis was 
203 nm, hydrodynamic injection of samples for 3 s 
under a pressure of 0.5 psi and the temperature of the 
capillary cartridge was 25 °C.
The background running buffer (BRB) was fil-
tered using 0.2 µm Anatop 25 Whatman inor-
ganic membrane filter (Maidstone, England) and 
degassed using Branson Ultrasonic 5510 degasser 
 (Danbury, CT, USA). A SympHonly (SB20) pH-
meter (Thermo Orion Beverly, MA, USA) was used 
for pH  measurements. Deionized water was prepared 
using a Barnstead NANO pure DIamond Analytical 
(USA) ultrapure water system.
Materials and reagents
All the chemicals used were of Analytical Reagent 
grade, and the solvents were of HPLC grade.
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•	 Sitagliptin Phosphate Monohydrate (SG), Met-
formin Hydrochloride (MF) and Phenformin 
Hydrochloride (IS) were purchased from AvaChem 
Scientific (San Antonio, TX, USA), Selleck 
Chemicals, LLC (Houston, TX, USA) and Sigma-
 Aldrich (Saint Louis, MO, USA) with labeled 
purity of 98%, 99% and $97%,  respectively. 
They were used as received without further 
purification.
•	 Janumet® 50–500 mg tablets; batch # 
mc20v005016803 and Janumet® 50–1000 mg 
 tablets; batch # mc20v005016825 (Merck Sharp & 
Dohme Corp., a subsidiary of Merck & Co., Inc., 
NJ, USA) were purchased from commercial 
sources in the local market. Each labeled to con-
tain 64.25 mg sitagliptin phosphate monohydrate 
(equivalent to 50 mg sitagliptin as a free base) and 
500 mg metformin hydrochloride and 64.25 mg 
sitagliptin phosphate monohydrate (equivalent to 
50 mg sitagliptin as a free base) and 1000 mg met-
formin hydrochloride, respectively.
•	 Sodium hydroxide, acetic acid and sodium dihy-
drogen phosphate (JT Baker, NJ, USA)
•	 Orthophosphoric acid 85%, sodium acetate and 
boric acid (Fisher Scientific, NJ, USA).
•	 Acetonitrile, methanol and ethanol (Sigma-
 Aldrich, MO, USA).
•	 Human plasma was purchased from Sigma- Aldrich 
(Saint Louis, MO, USA) as 0.45 µm filtered and 
lyophilized powder then it had been reconstituted 
with deionized water and kept frozen until used 
after gentle thawing.
Standard and sample solutions
Standard solutions
Stock solutions 1.0 mg/mL of SG, MF and IS were 
prepared in deionized water. Working solutions were 
prepared by further dilution of the stock solutions 
with BRB to give a final desired concentration. The 
solutions were stable for at least three months when 
kept in the refrigerator at 2 °C.
Background running buffer (BrB)
Optimized BRB solution was 60 mM sodium 
 dihydrogen phosphate buffer adjusted to pH 4.0 with 
orthophosphoric acid 85% and filtered through a 
0.2 µm membrane filter.
electrophoretic procedure
Before the first use, the capillary was conditioned by 
flushing with 1.0 M NaOH for 60 min, then with water 
for 30 min and BRB for 30 min at 0.5 psi  pressure. 
At the beginning of each working day, the capillary 
was rinsed with 0.1 M NaOH for 10 min, water for 
5 min and then with BRB for 5 min at 20 psi  pressure. 
Before each injection, the capillary was precondi-
tioned with 0.1 M NaOH (3 min), water (3 min) and 
BRB (3 min) at 20 psi pressure to maintain proper 
reproducibility of run-to-run injections. Injection was 
carried out under hydrodynamic pressure at 0.5 psi 
for 3 s. A diode- array UV detector was set at 203 nm 
with a bandwidth of 10 nm. The capillary temperature 
was kept constant at 25 °C and a voltage of +15 kV 
was applied.
Procedures
Construction of calibration graphs
Aliquots of the suitable drug stock or working stan-
dard solutions were transferred into a series of 4-mL 
vials so that the final concentrations were in the 
range of 10–100 µg/mL for SG and 50–500 µg/mL 
for MF. A constant 40 µL IS was added and the 
 volumes were diluted to 1 mL with the BRB. The 
peak area ratio (peak area of the studied drug/peak 
area of IS) was plotted versus the final concentration 
of each drug in µg/mL to get the calibration graph. 
 Alternatively, the corresponding regression equa-
tions were derived.
Analysis of Sg/MF synthetic mixtures
Aliquots of SG and MF standard solutions keeping the 
pharmaceutical ratio of 1:10 and 1:20 were transferred 
into a series of 4-mL vials, diluted with BRB after 
addition of 40 µL IS and mixed well. The above pro-
cedure described under “Construction of calibration 
graphs” was then applied. The percentage recoveries 
were calculated by referring to the calibration graphs, 
or using the corresponding regression equations.
Analysis of the studied drugs in their 
co-formulated tablets
Ten tablets of each type were weighed after their 
coats were removed by carefully rubbing with a clean 
tissue wetted with methanol and the average weight 
was calculated. Tablets were crushed to a fine powder. 
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An accurately weighed amount of the finely powdered 
tablets, equivalent to 1.0 mg SG and 7.78 mg MF in 
case of Janumet® 50–500 and equivalent to 1.0 mg SG 
and 15.56 mg MF in case of Janumet® 50–1000, was 
transferred to 10-mL volumetric flasks and 6 mL of 
deionized water was added. The flasks were sonicated 
for 30 min and vortex mixing for 15 min by Fisher 
vortex (Fisher Scientific), and then diluted to the 
mark with deionized water. The solution was filtered 
through Whatman filter paper and then filtered again 
using 0.2 µm Whatman inorganic membrane  filter. 
For analysis, an appropriate aliquot from the prepared 
sample solutions, spiked with 40 µL IS stock solutin 
(1.0 mg/mL), was diluted to 1 mL using BRB. The above 
procedure described under “Construction of calibration 
graphs” was then applied. The percentage recoveries 
were calculated by referring to the calibration graphs, 
or using the corresponding regression equations.
Procedure for spiked human plasma
Aliquots of human plasma (200 µL) spiked with 
increasing concentrations of the drugs were  transferred 
into series of 4-mL vials. After dilution to 2 mL 
with BRB, extraction treatment was carried out on a 
C18 SPE cartridge (Extra-SepTM, Fisher  Scientific). 
The cartridges were eluted with 2 mL  methanol: 
BRB (50% v/v) and the eluates were collected in 
a new 4-mL vials. A blank experiment was carried 
out simultaneously. The above procedure described 
under “Construction of calibration graphs” was then 
applied. The percentage recoveries were calculated 
by referring to the calibration graphs, or using the 
corresponding regression equations.
All solutions were filtered through a 0.2 µm mem-
brane filter and degassed for 5 min before injection to 
the CE system.
Results and Discussion
The proposed method permitted the separation of 
the two drugs in a reasonable time less than 8 min. 
Figure 2 shows a typical electropherogram for a syn-
thetic mixture of the two drugs under the described 
elecctrophoretic conditions. The retention times for 
MF and SG were 4.85 and 7.30 min, respectively. 
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Figure 2. Typical electropherogram for a synthetic mixture; MF (311.3 µg/mL), IS (40 µg/mL) and Sg (40 µg/mL) under the described elecctrophoretic 
conditions.
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Figure 3. effect of buffer ph on migration times and resolution.
notes: Operating conditions: 60 mM phosphate buffer, injection (3 s), 15 kV, 25 °C, 203 nm (bandwidth 10 nm). (MF and Sg: 0.1 g/mL).
The proposed method offers good sensitivity as about 
2.11 µg/mL of MF and 0.49 µg/mL of SG could be 
detected accurately. It also permitted the quantifica-
tion of the drugs in their co-formulated tablets and in 
human plasma.
Optimization of Ce conditions
In CZE the buffer type, pH and concentration is a key 
strategy for optimizing the separation of  ionizable 
analytes as it determines the degree of the analyte 
ionization, its electrophoretic mobility and the mag-
nitude of the electroosmotic flow (EOF). As SG has 
pKa value of 7.7
27 and MF has pKa value 11.5,
33 they 
are positively charged under acidic conditions and 
can be analyzed by CZE. Several running buffers 
such as phosphate, acetate and borate at different pHs 
and molarities were tested for CZE analysis and the 
best results were obtained in phosphate buffer taking 
into consideration of different parameters (migration 
time, resolution, peak shape, height, baseline noise 
and the electric current produced).
The effect of phosphate buffer ph
The effect of the buffer pH was investigated 
within the range of 3.0–6.0 at a 60 mM phosphate 
buffer  concentration. The results demonstrated that 
SG was easily separated from MF in this pH range 
and both resolution and migration times decreased 
with increasing pH. At pH 6 a non-ionizable SG peak 
was appeared as its pKa value is 7.7. Taking into con-
sideration  resolution, peak symmetry and migration 
time, pH 4.0 was selected as optimum pH (Fig. 3).
The effect of phosphate buffer concentration
Buffer concentration has also a significant effect on 
the separation performance through its influence 
on the EOF and the current produced in the capillary. 
The effect of phosphate concentration of running 
 buffer was examined by varying the concentration 
from 10 to 100 mM. As shown in Figure 4, with an 
increasing in phosphate concentration, both resolu-
tion and migration times increased. A 60 mM con-
centration of phosphate buffer was chosen in order 
to reduce the analysis time while maintaining good 
resolution (≈14) and acceptable current (≈30 µA).
The effect of organic modifiers
The addition of organic modifiers to the running buffer 
was considered because they affect several parameters 
such as viscosity, dielectric constant and zeta potential. 
In order to investigate the effect of organic modifiers, 
methanol, ethanol and acetonitrile were added at vari-
ous concentrations (5, 10 and 15% v/v) to the running 
buffer of 60 mM phosphate buffer pH 4.0. No apprecia-
ble improvements were observed, but migration times 
increased significantly with the addition of organic 
modifiers. Therefore, no organic modifiers were added 
to the running buffer in the proposed analysis method.
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The effect of applied voltage
The applied voltage effect was investigated under the 
optimized conditions selected above from 5 to 30 kV. 
As expected, increasing the applied voltage increases 
the EOF, leading to shorter analysis time, better sepa-
ration and higher efficiencies. However, lowering the 
applied voltage than 10 kV decreases the EOF so the 
peaks of MF and SG were not resolved and increasing 
applied voltage exhibits higher currents and produces 
Joule’s heating. To limit this heating inside the capil-
lary, the maximum applied voltage was chosen from 
an Ohm’s plot (current versus voltage). The selected 
voltage was 15 kV (current (≈30 µA)).
The effect of injection time
Injection time affects the peak width and peak height. 
Sample solutions were hydrodynamically injected at 
0.5 psi while the injection time was varied from 1.0 
to 7.0 s. After 6.0 s, the peak widths of SG and MF 
were increased and the peak shapes were deformed, 
so 3.0 s was selected as the optimum injection time.
The effect of capillary cartridge temperature
Controlling the temperature of the capillary cartridge is 
important in capillary electrophoresis. The  viscosity of 
the running buffer is dependent on capillary  temperature, 
so changes in temperature cause changes in EOF, elec-
trophoretic mobilities and injection  volume. The influ-
ence of the temperature on analysis was investigated at 
20, 25 and 30 °C. The selected temperature was 25 °C 
because it provided the best resolution and the gener-
ated current was not more than 30 µA.
Selection of internal standard (IS)
The use of an IS is recommended to compensate 
for injection errors, minor fluctuations effect of the 
migration time and improve the quantitative  analysis. 
Then phenformin hydrochloride was chosen as it 
possesses pKa value 11.8
33 and its molecular weight 
more than MF and less than SG so it will be posi-
tively charged under the optimized condition and as 
expected it eluted after MF and before SG.
Selection of the detection wavelength
In order to optimize sensitivity and detection limit 
of the method, a multiwavelength detection system 
(190–300 nm) was used in the CE system. For the 
simultaneous determination of SG and MF the maxi-
mum detection sensitivities (the best signal to-noise 
ratios) were obtained at 203 nm (bandwidth 10 nm). 
Figure 5 and Table 1 show the effect of detection 
wavelength on the proposed CZE method.
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Figure 4. effect of buffer conc. on migration times and resolution.
notes: Operating conditions: ph 4.0 phosphate buffer, injection (3 s), 15 kV, 25 °C, 203 nm (bandwidth 10 nm). (MF and Sg: 0.1 g/mL).
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peak area) against the drug concentration as shown 
in  Figure 6. The concentration ranges were found 
to be in linear in the range of 10–100 µg/mL and 
50–500 µg/mL for SG and MF, respectively. Linear 
regression analysis of the data gave the following 
equations:
 P = 0.0121 C-0.0597  (r = 0.9999) for SG
 P = 0.0149 C-0.0703  (r = 0.9999) for MF
where P is the peak area ratio, C is the concentra-
tion of the drug in µg/mL and r is the correlation 
coefficient.
Statistical analysis of the data gave high value of 
the correlation coefficient (r) of the regression equa-
tion, small values of the standard deviation of residu-
als (Sy/x), of intercept (Sa), and of slope (Sb), and small 
value of the percentage relative standard deviation 
and the percentage relative error (Table 2). These data 
proved the linearity of the calibration graph.
Limit of quantitation (LOQ) and limit  
of detection (LOD)
LOQ and LOD were calculated according to ICH 
Q2 (R1) recommendations using the following 
equation:34
 LOQ = 10 Sa/b and LOD = 3.3 Sa/b
where Sa = standard deviation of the intercept and 
b = slope of the calibration curve.
LOQ values were found to be 1.48, 6.39 µg/mL 
while LOD values were found to be 0.49, 2.11 µg/mL 
for SG and MF, respectively.
Accuracy and precision
To prove the accuracy and utility of the proposed method, 
the results of the assay of SG and MF were compared 
with those of the reference method.24  Statistical analysis 
of the results using Student’s t-test and variance ratio 
F-test35 revealed no significant difference between the 
performance of the two methods regarding the accu-
racy and precision, respectively (Table 3).
The reference method depends on the analysis of 
SG—MF binary mixture by derivative spectropho-
tometry. Where, SG and MF were assayed by first 
derivative zero crossing technique.24
Validation of the method
Validation of the proposed CZE method was per-
formed with respect to stability, linearity and range, 
specificity, limit of detection (LOD), limit of quan-
titation (LOQ), accuracy, precision and robustness 
according to the ICH Guidelines.34
Linearity
A linear relationship was established by plotting 
the peak area ratio (the studied drug peak area/IS 
Simultaneous determination of sitagliptin and metformin by CZe
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Table 1. effect of detection wavelength on Sg, MF and IS peak area: (311.3 µg/mL MF, 40 µg/mL IS and 40 µg/mL Sg).
Wavelength  
(nm)
peak(s) area % decrease in peak area  
(compared to 203 nm)MF Is sG
MF Is sG
203 263498 61208 25475 0.00 0.00 0.00
210 208144 40353 18657 21.00 34.07 26.76
220 174725 26576 7199 33.69 56.58 71.74
236 182427 23085 --------* 30.76 62.28 100.00
267 3426 ---------* ---------* 98.69 100.00 100.00
note: *not detected.
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Figure 6. Calibration curve for the determination of (A) Sg, (B) MF by the proposed CZe method under the described elecctrophoretic conditions.
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Table 2. Performance data for the determination of the 
studied drugs by the proposed CZe method.
parameter sG MF
Linearity range (µg/mL) 10–100 50–500
Intercept (a) -0.0597 -0.0703
Slope (b) 0.0121 0.0149
Correlation coefficient (r) 0.9999 0.9999
SD of residuals (Sy/x) 0.0042 0.0287
SD of intercept (Sa) 0.0018 0.0095
SD of slope (Sb) 0.0001 0.0001
Percentage relative standard  
deviation, % rSD
0.769 0.960
Percentage relative error, % error 0.273 0.303
Limit of detection, LOD (µg/mL) 0.49 2.11
Limit of quantitation, LOQ (µg/mL) 1.48 6.39
Table 3. Assay results for the determination of the studied drugs in pure form by the CZe and reference methods.
compound proposed method Reference method24
Amount taken  
(μg/mL)
Amount found  
(μg/mL)
% found % found
Sg 10.0 10.08 100.80 101.82
20.0 19.93 99.66 100.89
30.0 30.07 100.24 99.78
40.0 39.69 99.23 99.15
50.0 50.91 101.81 101.55
60.0 60.05 100.09
80.0 80.12 100.15
100.0 100.20 100.20
Mean ± SD 100.27 ± 0.77 100.64 ± 1.16
t 0.69 (1.79)
F 2.21 (4.12)
MF 50.0 49.71 99.43 100.00
100.0 98.42 98.42 100.25
150.0 151.89 101.26 100.33
200.0 198.99 99.50 99.13
250.0 246.55 98.62 100.40
300.0 303.45 101.15
350.0 351.28 100.37
400.0 397.13 99.28
450.0 447.25 99.39
500.0 500.08 100.02
Mean ± SD 99.74 ± 0.96 100.02 ± 0.52
t 0.59 (1.77)
F 3.38 (5.99)
notes: each result is the average of three separate determinations. The values between parentheses are the tabulated t and F values at P = 0.05.35
Repeatability (intraday) and intermediate precision 
(interday) were assessed using three concentrations 
and three replicates of each concentration. The rela-
tive standard deviations were found to be very small 
indicating reasonable repeatability and intermediate 
precision of the proposed method (Table 4).
Stability
Stability of the standard solutions of SG and MF, 
stored at 2 °C, were evaluated at various time points 
over 3 months. The concentrations of freshly pre-
pared solutions and those aged for 3 months were cal-
culated by the method developed and the difference 
between them was found to be less than 0.50%. These 
solutions can therefore be used during this interval of 
time without the results being affected.
robustness of the method
The robustness of the proposed method was 
evaluated by the constancy of the peak area ratio 
with the deliberated changes in the experimental 
 parameters; these parameters include (phosphate 
buffer pH 4.0 ± 0.2, Phosphate buffer concentra-
tion 60 ± 5 mM injection time 3 ± 1 s, applied volt-
age 15 ± 2 kV and capillary cartridge temperature 
25 ± 2 °C). Analyses were carried out in triplicate 
and only one parameter was changed in the experi-
ments at a time. These minor changes didn’t greatly 
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Table 4. Accuracy and precision data for the determination of Sg and MF by the proposed CZe method.
parameters sG concentration  
(μg/mL)
MF concentration  
(μg/mL)
10.0 20.0 30.0 155.6 311.3 466.9
Intraday
% found 101.02 99.39 100.23 99.02 99.80 100.33
100.36 98.97 99.56 98.94 100.22 99.75
99.86 100.26 99.91 99.98 99.35 101.2
(x–) 100.41 99.54 99.90 99.31 99.79 100.43
±SD 0.58 0.66 0.33 0.57 0.44 0.73
% rSD 0.58 0.66 0.34 0.58 0.44 0.73
% error 0.34 0.38 0.19 0.34 0.25 0.42
Interday
% found 98.36 101.06 98.19 99.54 98.61 101.60
99.02 100.98 99.86 100.13 99.09 100.11
100.67 99.35 100.29 98.70 100.06 98.90
(x–) 99.35 100.46 99.45 99.46 99.25 100.20
±SD 1.19 0.97 1.11 0.72 0.74 1.35
% rSD 1.20 0.96 1.12 0.72 0.75 1.35
% error 0.69 0.56 0.64 0.42 0.43 0.78
note: each result is the average of three separate determinations.
Table 5. robustness data (40 µg/mL Sg, 311.3 µg/mL MF 
and 40 µg/mL IS).
parameters Migration times  
(min)
peak area  
ratios
sG MF sG MF
Standard 7.30 4.85 0.38 4.07
Buffer ph
 3.84 7.35 4.79 0.38 4.07
 4.24 7.20 4.80 0.38 4.07
Buffer concocentration (mM)
 55 7.25 4.75 0.37 4.06
 65 7.35 4.85 0.38 4.07
Injection time (s)
 2 7.25 4.78 0.36 3.97
 4 7.27 4.83 0.38 4.07
Applied voltage (kV)
 13 7.55 5.15 0.38 4.15
 17 7.05 4.65 0.40 4.05
Capillary temp. (°C)
 23 7.45 4.90 0.38 4.10
 27 7.30 4.80 0.37 4.11
note: each result is the average of three separate determinations.
affect the peak area ratio and migration times of the 
studied drugs (Table 5).
Specificity
The specificity of the method was investigated by 
observing any interference encountered from  common 
tablet excipients and it was confirmed that the sig-
nals measured was caused only by the analytes. Each 
film-coated tablet of Janumet® contains the following 
inactive ingredients: microcrystalline cellulose, poly-
vinylpyrrolidone, sodium lauryl sulfate, and sodium 
stearyl fumarate. In addition, the film coating contains 
the following inactive ingredients: polyvinyl alcohol, 
polyethylene glycol, talc, titanium dioxide, red iron 
oxide, and black iron oxide. It was found that these 
compounds did not interfere with the results of the 
proposed method. As shown in Figures 7 and 8 the 
tablets and plasma electropherograms did not show 
any additional peaks when compared to SG/MF syn-
thetic mixture electropherograms which confirm the 
specificity of the method.
Applications
Analysis of Sg/MF in synthetic  
mixtures and co-formulated tablets
The proposed CZE method was applied to the simulta-
neous determination of SG and MF in synthetic mix-
tures in the medicinally recommended ratio of 1:10 and 
1:20. Furthermore, the proposed method was success-
fully applied to their determination in co- formulated 
tablets (Fig. 7). The results shown in Tables 6 and 7 
are in good agreement with those obtained using the 
reference method.24 Statistical analysis of the results 
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Figure 7. Application of the proposed method for the simultaneous determination of Sg and MF in co-formulated tablets. (A) Janumet® 50–500 tab. 
(a) MF: 311.3 µg/mL (b) IS: 40 µg/mL (c) Sg: 40 µg/mL. (B) Janumet® 50–1000 tab. (a) MF: 466.9 µg/mL (b) IS: 40 µg/mL (c) Sg: 40 µg/mL.
obtained using Student’s t-test and variance ratio 
F-test35 revealed no significant  difference between the 
performance of the two methods regarding the accu-
racy and precision, respectively.
Biological application
MF is slowly absorbed after oral  administration. 
The reported peak plasma concentrations of 
0.59 to 1.30 mg/L and 1.80 to 4.0 mg/L were 
attained in about 2 hours following oral dose of 
50 mg and 150 mg, respectively.33 SG is rapidly 
absorbed from gastrointestinal tract with absolute 
oral bioavailability of about 87%. The maximum 
plasma concentration of SG was reported 950 nM 
(0.497 mg/L) following a single oral dose of 
100 mg.36 The electropherograms for human plasma 
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Figure 8. Application of the proposed method for the simultaneous determination of Sg and MF in spiked human plasma performed in long time (20 
min) to show that there is no additional peak observed for the plasma protein. (A) Blank plasma sample. (B) Plasma sample spiked with 50 µg/mL MF, 
10 µg/mL IS and 10 µg/mL Sg.
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Table 6. Assay results for the determination of the studied drugs in their synthetic mixture and reference methods.
prepared ratio Amount taken (μg/mL) % founda
sG MF proposed cZe method Reference method24
sG MF sG MF
1:10 10.0 77.8 100.24 100.02 101.82 100.00
20.0 155.7 98.76 100.01 100.89 100.25
30.0 233.5 99.24 99.69 99.78 100.33
40.0 311.3 100.37 100.10 99.15 99.13
50.0 389.1 99.92 101.06 101.55 100.40
(x–) 99.71 100.18 100.64 100.02
±SD ±0.69 ±0.52 ±1.16 ±0.52
Student’s t-test 1.56 (2.31)b 0.47 (2.31)
F-test 2.78 (6.39) 1.01 (6.39)
1:20 10.0 155.6 101.19 100.51 101.82 100.00
20.0 311.3 101.50 99.69 100.89 100.25
30.0 466.9 100.23 99.86 99.78 100.33
99.15 99.13
101.55 100.40
(x–) 100.97 100.02 100.64 100.02
±SD ±0.66 ±0.43 ±1.16 ±0.52
Student’s t-test 0.45 (2.45) 0.01 (2.45)
F-test 2.99 (19.25) 1.45 (19.25)
notes: aThe average of three separate determinations; bthe figures between parentheses are the tabulated values of t and F at P = 0.05.35
Table 7. Assay results for the determination of the studied drugs in their co-formulated tablets.
preparation Amount taken  
(μg/mL)
Amount founda  
(μg/mL)
% found Reference  
method24
sG MF sG MF sG MF sG MF
1-Janumet®  
50–500 tablets
50.0 389.1 49.89 388.24 99.78 99.78 97.59 98.33
40.0 311.3 39.69 309.46 99.22 99.41 99.13 99.87
30.0 233.5 29.62 232.31 98.74 99.49 99.41 99.10
20.0 155.7 19.93 155.75 99.65 100.03
10.0 77.8 9.85 77.89 98.53 100.11
(x–) 99.18 99.76 98.71 99.10
±SD ±0.55 ±0.31 ±0.98 ±0.77
% rSD 0.55 0.31 0.99 0.77
% error 0.25 0.14 0.58 0.45
t 0.90 (2.45)b 1.76 (2.45)
F 3.22 (6.94) 6.10 (6.94)
2-Janumet®  
50–1000 tablets
30.0 466.9 29.92 464.94 99.72 99.58 100.58 100.17
20.0 311.3 20.28 308.78 101.42 99.19 99.56 100.13
10.0 155.6 10.23 156.24 102.34 100.41 99.65 101.00
(x–) 101.16 99.73 99.94 100.43
±SD ±1.32 ±0.62 ±0.57 ±0.49
% rSD 1.31 0.63 0.57 0.49
% error 0.76 0.36 0.33 0.28
t 1.46 (2.78) 1.54 (2.78)
F 1.37 (19.00) 1.60 (19.00)
notes: aThe average of three separate determinations; bthe figures between parentheses are the tabulated values of t and F at P = 0.05.35
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Table 8. Assay results for the determination of the studied 
drugs in spiked human plasma using the proposed 
method.
compound Amount taken  
(μg/mL)
Amount found  
(μg/mL)
% found
Sg 10.0 10.09 100.93
20.0 19.71 98.53
30.0 29.99 99.98
(x–) 99.81
±SD ±1.21
% rSD 1.21
% error 0.70
MF 50.0 49.26 98.51
60.0 58.92 98.2
70.0 70.64 100.91
(x–) 99.21
±SD ±1.48
% rSD 1.49
% error 0.86
of blank and that spiked with the studied drugs are 
shown in Figure 8. The blank plasma exhibited 
no peaks in the electropherogram. The results are 
abridged in Table 8.
conclusion
A new, simple, accurate and sensitive CZE method 
was explored for the simultaneous determination 
of SG and MF in binary mixture. The developed 
method has distinct advantages regarding analysis 
time, sensitivity and cost compared with those of 
the previously reported methods. Limits of detec-
tion of 0.49, 2.11 µg/mL and limits of quantitation of 
1.48, 6.39 µg/mL for SG and MF, respectively were 
obtained. It could be applied to the analysis of the 
drugs in their co-formulated tablets. It also offers the 
possibility to determine the studied drugs in in human 
plasma. It seems to be very promising for the thera-
peutic drug monitoring of patients undergoing treat-
ment with the studied drugs.
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